1
|
Chowdhury R, Eslami S, Pham CV, Rai A, Lin J, Hou Y, Greening DW, Duan W. Role of aptamer technology in extracellular vesicle biology and therapeutic applications. NANOSCALE 2024; 16:11457-11479. [PMID: 38856692 DOI: 10.1039/d4nr00207e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2024]
Abstract
Extracellular vesicles (EVs) are cell-derived nanosized membrane-bound vesicles that are important intercellular signalling regulators in local cell-to-cell and distant cell-to-tissue communication. Their inherent capacity to transverse cell membranes and transfer complex bioactive cargo reflective of their cell source, as well as their ability to be modified through various engineering and modification strategies, have attracted significant therapeutic interest. Molecular bioengineering strategies are providing a new frontier for EV-based therapy, including novel mRNA vaccines, antigen cross-presentation and immunotherapy, organ delivery and repair, and cancer immune surveillance and targeted therapeutics. The revolution of EVs, their diversity as biocarriers and their potential to contribute to intercellular communication, is well understood and appreciated but is ultimately dependent on the development of methods and techniques for their isolation, characterization and enhanced targeting. As single-stranded oligonucleotides, aptamers, also known as chemical antibodies, offer significant biological, chemical, economic, and therapeutic advantages in terms of their size, selectivity, versatility, and multifunctional programming. Their integration into the field of EVs has been contributing to the development of isolation, detection, and analysis pipelines associated with bioengineering strategies for nano-meets-molecular biology, thus translating their use for therapeutic and diagnostic utility.
Collapse
Affiliation(s)
- Rocky Chowdhury
- School of Medicine, Deakin University, and IMPACT Strategic Research Centre, Waurn Ponds, VIC, 3216, Australia.
| | - Sadegh Eslami
- Molecular Proteomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
| | - Cuong Viet Pham
- Molecular Imaging and Theranostics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC, 3004, Australia
| | - Alin Rai
- Molecular Proteomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
- Department of Cardiovascular Research, Translation and Implementation, and La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Australia
| | - Jia Lin
- Department of Biochemistry and Molecular Biology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, China
| | - Yingchu Hou
- Laboratory of Tumor Molecular and Cellular Biology College of Life Sciences, Shaanxi Normal University 620 West Chang'an Avenue, Xi'an, Shaanxi, 710119, China
| | - David W Greening
- Molecular Proteomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
- Department of Cardiovascular Research, Translation and Implementation, and La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Australia
| | - Wei Duan
- School of Medicine, Deakin University, and IMPACT Strategic Research Centre, Waurn Ponds, VIC, 3216, Australia.
| |
Collapse
|
2
|
Cao X, Chen C, Zhu Q. Biosensors based on functional nucleic acids and isothermal amplification techniques. Talanta 2023; 253:123977. [PMID: 36201957 DOI: 10.1016/j.talanta.2022.123977] [Citation(s) in RCA: 24] [Impact Index Per Article: 24.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2022] [Revised: 09/20/2022] [Accepted: 09/27/2022] [Indexed: 12/13/2022]
Abstract
In the past few years, with the in-depth research of functional nucleic acids and isothermal amplification techniques, their applications in the field of biosensing have attracted great interest. Since functional nucleic acids have excellent flexibility and convenience in their structural design, they have significant advantages as recognition elements in biosensing. At the same time, isothermal amplification techniques have higher amplification efficiency, so the combination of functional nucleic acids and isothermal amplification techniques can greatly promote the widespread application of biosensors. For the purpose of further improving the performance of biosensors, this review introduces several widely used functional nucleic acids and isothermal amplification techniques, as well as their classification, basic principles, application characteristics, and summarizes their important applications in the field of biosensing. We hope to provide some references for the design and construction of new tactics to enhance the detection sensitivity and detection range of biosensing.
Collapse
Affiliation(s)
- Xiuen Cao
- Xiangya School of Pharmaceutical Sciences in Central South University, Changsha, 410013, Hunan, China.
| | - Chuanpin Chen
- Xiangya School of Pharmaceutical Sciences in Central South University, Changsha, 410013, Hunan, China.
| | - Qubo Zhu
- Xiangya School of Pharmaceutical Sciences in Central South University, Changsha, 410013, Hunan, China.
| |
Collapse
|
3
|
Novel Aptamer-Based Small-Molecule Drug Screening Assay to Identify Potential Sclerostin Inhibitors against Osteoporosis. Int J Mol Sci 2021; 22:ijms22158320. [PMID: 34361085 PMCID: PMC8348959 DOI: 10.3390/ijms22158320] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2021] [Revised: 07/27/2021] [Accepted: 07/29/2021] [Indexed: 12/19/2022] Open
Abstract
A novel aptamer-based competitive drug screening platform for osteoporosis was devised in which fluorescence-labeled, sclerostin-specific aptamers compete with compounds from selected chemical libraries for the binding of immobilized recombinant human sclerostin to achieve high-throughput screening for potential small-molecule sclerostin inhibitors and to facilitate drug repurposing and drug discovery. Of the 96 selected inhibitors and FDA-approved drugs, six were shown to result in a significant decrease in the fluorescence intensity of the aptamer, suggesting a higher affinity toward sclerostin compared with that of the aptamer. The targets of these potential sclerostin inhibitors were correlated to lipid or bone metabolism, and several of the compounds have already been shown to be potential osteogenic activators, indicating that the aptamer-based competitive drug screening assay offered a potentially reliable strategy for the discovery of target-specific new drugs. The six potential sclerostin inhibitors suppressed the level of both intracellular and/or extracellular sclerostin in mouse osteocyte IDG-SW3 and increased alkaline phosphatase activity in IDG-SW3 cells, human bone marrow-derived mesenchymal stem cells and human fetal osteoblasts hFOB1.19. Potential small-molecule drug candidates obtained in this study are expected to provide new therapeutics for osteoporosis as well as insights into the structure-activity relationship of sclerostin inhibitors for rational drug design.
Collapse
|
4
|
Leeder WM, Giehler F, Joswig J, Göringer HU. Bioinspired Design of Lysolytic Triterpenoid-Peptide Conjugates that Kill African Trypanosomes. Chembiochem 2019; 20:1251-1255. [PMID: 30609206 DOI: 10.1002/cbic.201800674] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2018] [Revised: 12/19/2018] [Indexed: 11/07/2022]
Abstract
Humans have evolved a natural immunity against Trypanosoma brucei infections, which is executed by two serum (lipo)protein complexes known as trypanolytic factors (TLF). The active TLF ingredient is the primate-specific apolipoprotein L1 (APOL1). The protein has a pore-forming activity that kills parasites by lysosomal and mitochondrial membrane fenestration. Of the many trypanosome subspecies, only two are able to counteract the activity of APOL1; this illustrates its evolutionarily optimized design and trypanocidal potency. Herein, we ask whether a synthetic (syn) TLF can be synthesized by using the design principles of the natural TLF complexes but with different chemical building blocks. We demonstrate the stepwise development of triterpenoid-peptide conjugates, in which the triterpenoids act as a cell-binding, uptake and lysosomal-transport modules and the synthetic peptide GALA acts as a pH-sensitive, pore-forming lysolytic toxin. As designed, the conjugate kills infective-stage African trypanosomes through lysosomal lysis thus demonstrating a proof-of-principle for the bioinspired, forward-design of a synTLF.
Collapse
Affiliation(s)
- W-Matthias Leeder
- Molecular Genetics, Darmstadt University of Technology, Schnittspahnstrasse 10, 64287, Darmstadt, Germany
| | - Fabian Giehler
- Molecular Genetics, Darmstadt University of Technology, Schnittspahnstrasse 10, 64287, Darmstadt, Germany.,Present address: Helmholtz Zentrum München für Gesundheit und Umwelt (GmbH), Research Unit Gene Vectors Munich (Germany) and, German Center for Infection Research (DZIF), Partner Site Munich, Marchionistrasse 25, 81377, Munich, Germany
| | - Juliane Joswig
- Molecular Genetics, Darmstadt University of Technology, Schnittspahnstrasse 10, 64287, Darmstadt, Germany
| | - H Ulrich Göringer
- Molecular Genetics, Darmstadt University of Technology, Schnittspahnstrasse 10, 64287, Darmstadt, Germany
| |
Collapse
|
5
|
Liu N, Tan Y, Hu Y, Meng T, Wen L, Liu J, Cheng B, Yuan H, Huang X, Hu F. A54 Peptide Modified and Redox-Responsive Glucolipid Conjugate Micelles for Intracellular Delivery of Doxorubicin in Hepatocarcinoma Therapy. ACS APPLIED MATERIALS & INTERFACES 2016; 8:33148-33156. [PMID: 27934140 DOI: 10.1021/acsami.6b09333] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Redox-responsive nanomaterials applied in drug delivery systems (DDS) have attracted an increasing attention in pharmaceutical research as a carrier for antitumor therapy. However, there would be unwanted drug release from a redox-responsive DDS with no selection at nontarget sites, leading to undesirable toxicities in normal tissues and cells. Here, an A54 peptide modified and PEGylated reduction cleavable glucolipid conjugate (A54-PEG-CSO-ss-SA, abbreviated to APCssA) was designed for intracellular delivery of doxorubicin (DOX). The synthesized APCssA could be assembled via micellization self-assembly in aqueous water above the critical micelle concentration (54.9 μg/mL) and exhibited a high drug encapsulation efficiency (77.92%). The APCssA micelles showed an enhanced redox sensitivity in that the disulfide bond could be degraded quickly and the drug would be released from micelles in 10 mM levels of glutathione (GSH). The cellular uptake studies highlighted the affinity of APCssA micelles toward the hepatoma cells (BEL-7402) compared to that toward HepG2 cells. In contrast with the nonresponsive conjugate, the drug was released from APCssA micelles more quickly in 10 mM level of GSH concentration (tumor cells). Moreover, the DOX-loaded APCssA micelles displayed an increased cytotoxicity which was 1.6- to 2.0-fold that of unmodified and nonresponsive micelles. In vivo, the APCssA micelles had stronger distribution to liver and hepatoma tissue and prolonged the circulation and retention time, while the drug release only occurred in the tumor tissue. The APCssA/DOX showed the tumor inhibition rate equal to that of commercial doxorubicin hydrochloric without negative consequence. This study suggested that the APCssA/DOX showed promising potential to treat the tumor for its special tumor targeting, selective intracellular drug release, enhanced antitumor activity, and reduced toxicity on normal tissues.
Collapse
Affiliation(s)
- Na Liu
- College of Pharmaceutical Science, Zhejiang University , 866 Yuhangtang Road, Hangzhou 310058, PR China
| | - Yanan Tan
- College of Pharmaceutical Science, Zhejiang University , 866 Yuhangtang Road, Hangzhou 310058, PR China
| | - Yingwen Hu
- College of Pharmaceutical Science, Zhejiang University , 866 Yuhangtang Road, Hangzhou 310058, PR China
| | - Tingting Meng
- College of Pharmaceutical Science, Zhejiang University , 866 Yuhangtang Road, Hangzhou 310058, PR China
| | - Lijuan Wen
- College of Pharmaceutical Science, Zhejiang University , 866 Yuhangtang Road, Hangzhou 310058, PR China
| | - Jingwen Liu
- College of Pharmaceutical Science, Zhejiang University , 866 Yuhangtang Road, Hangzhou 310058, PR China
| | - Bolin Cheng
- College of Pharmaceutical Science, Zhejiang University , 866 Yuhangtang Road, Hangzhou 310058, PR China
| | - Hong Yuan
- College of Pharmaceutical Science, Zhejiang University , 866 Yuhangtang Road, Hangzhou 310058, PR China
| | - Xuan Huang
- Department of Pharmacy, School of Medicine Science, Jiaxing University , Zhejiang 314001, PR China
| | - Fuqiang Hu
- College of Pharmaceutical Science, Zhejiang University , 866 Yuhangtang Road, Hangzhou 310058, PR China
| |
Collapse
|
6
|
He X, Chen J, Yie SM, Ye SR, Dong DD, Li K. Using a sequence of estrogen response elements as a DNA aptamer for estrogen receptors in vitro. Nucleic Acid Ther 2015; 25:152-61. [PMID: 25734367 DOI: 10.1089/nat.2014.0521] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Estrogen receptors (ERs) are overexpressed in approximately 70% of breast cancer cases, and they play an important role in tumorigenesis. ERs are strong predictive factors for measuring responses to hormonal therapies. Aptamers are short and single stranded oligonucleotides that are able to recognize target molecules with high affinity. In the present study, we selected and synthesized an oligonucleotide, which has a similar sequence to estrogen response element in the Xenopus Vitellogenin A2 gene. The synthesized oligonucleotide was evaluated by using immunostaining of paraffin-embedded breast cancer tissues and treating MCF-7 human mammary carcinoma cell line in vitro. We found that the synthesized oligonucleotide had a high binding affinity to ER similar to estradiol. Using a specific anti-ER antibody as a standard control, we showed that the synthesized oligonucleotide specifically recognized and immunostained tumor cells of breast cancer without cross-reaction with normal tissues. The overall agreement of ER detection between the anti-ER antibody and the ER aptamer was 97.1% (kappa value=0.943; 95% CI=0.879-1.006; p<0.002). Similar to tamoxifen or fulvestrant, the oligonucleotide also had an inhibitory effect on cell proliferation of MCF-7 cell line in a dose- and time-dependent fashion but had no cytotoxic effect on human normal mammary epithelial cells. Therefore, the synthesized oligonucleotide may be used as an aptamer for immunostaining of paraffin-embedded tissue sections for breast cancer diagnosis, as well as a potential ER antagonist in the treatment of breast cancer.
Collapse
Affiliation(s)
- Xu He
- 1Core Laboratory, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Chengdu, Sichuan, China
| | - Jie Chen
- 1Core Laboratory, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Chengdu, Sichuan, China
| | - Shang-mian Yie
- 1Core Laboratory, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Chengdu, Sichuan, China.,2Research and Development Center, Sichuan HeLi Bio-pharmaceutical Co. Ltd., Sichuan HeBang Group, Chengdu, Sichuan, China
| | - Shang-rong Ye
- 2Research and Development Center, Sichuan HeLi Bio-pharmaceutical Co. Ltd., Sichuan HeBang Group, Chengdu, Sichuan, China
| | - Dan-Dan Dong
- 3Department of Pathology, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Chengdu, Sichuan, China
| | - Ke Li
- 3Department of Pathology, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Chengdu, Sichuan, China
| |
Collapse
|
7
|
Abstract
IMPORTANCE OF THE FIELD Therapeutic aptamers are synthetic, structured oligonucleotides that bind to a very broad range of targets with high affinity and specificity. They are an emerging class of targeting ligand that show great promise for treating a number of diseases. A series of aptamers currently in various stages of clinical development highlights the potential of aptamers for therapeutic applications. AREAS COVERED IN THIS REVIEW This review covers in vitro selection of oligonucleotide ligands, called aptamers, from a combinatorial library using the Systematic Evolution of Ligands by Exponential Enrichment process as well as the other known strategies for finding aptamers against various targets. WHAT THE READER WILL GAIN Readers will gain an understanding of the highly useful strategies for successful aptamer discovery. They may also be able to combine two or more of the presented strategies for their aptamer discovery projects. TAKE HOME MESSAGE Although many processes are available for discovering aptamers, it is not easy to discover an aptamer candidate that is ready to move toward pharmaceutical drug development. It is also apparent that there have been relatively few therapeutic advances and clinical trials undertaken due to the small number of companies that participate in aptamer development.
Collapse
|
8
|
Han B, Zhao C, Yin J, Wang H. High performance aptamer affinity chromatography for single-step selective extraction and screening of basic protein lysozyme. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 903:112-7. [PMID: 22841745 DOI: 10.1016/j.jchromb.2012.07.003] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2012] [Revised: 07/04/2012] [Accepted: 07/11/2012] [Indexed: 12/24/2022]
Abstract
A DNA aptamer based high-performance affinity chromatography is developed for selective extraction and screening of a basic protein lysozyme. First, a poly(glycidyl methacrylate-co-ethylene dimethacrylate) monolithic column was synthesized in situ by thermally initiated radical polymerization, and then an anti-lysozyme DNA aptamer was covalently immobilized on the surface of the monolith through a 16-atom spacer arm. The target protein lysozyme but non-target proteins can be trapped by the immobilized anti-lysozyme DNA aptamer. In contrast, lysozyme cannot be trapped by the immobilized oligodeoxynucleotide that does not contain the sequence of the anti-lysozyme DNA aptamer. The study clearly demonstrates the trapping of lysozyme by the immobilized anti-lysozyme DNA aptamer is mainly due to specific recognition rather than simple electrostatic interaction of positively charged protein and the negatively charged DNA. The inter-day precision was determined as 0.8% for migration time and 4.2% for peak area, respectively. By the use of aptamer affinity monolith, a screening strategy is developed to selectively extract lysozyme from chicken egg white, showing the advantages of high efficiency, low cost and ease-of-operation.
Collapse
Affiliation(s)
- Bin Han
- State Key Laboratory of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing 100086, PR China
| | | | | | | |
Collapse
|
9
|
Göringer HU. Parasite-specific aptamers as biosynthetic reagents and potential pharmaceuticals. Trends Parasitol 2012; 28:106-13. [PMID: 22300805 DOI: 10.1016/j.pt.2011.12.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2011] [Revised: 12/28/2011] [Accepted: 12/29/2011] [Indexed: 10/14/2022]
Abstract
Aptamers are short, synthetic nucleic acid molecules. They are generated by a Darwinian-type in vitro evolution method known as 'systematic evolution of ligands by exponential enrichment' (SELEX). SELEX represents an experimental platform to identify rare ligands with predetermined functionality from combinatorial nucleic acid libraries. Since its discovery about 20 years ago the method has been instrumental in identifying a large number of aptamers that recognize targets of very different chemistry and molecular complexity. Although aptamers have been converted into sophisticated biomolecular tools for a diverse set of technologies, only a limited number of aptamers have been selected as binding reagents for parasites or parasite-derived molecules. Here the published examples of aptamers that target Leishmania-, Trypanosoma- and Plasmodia-specific molecules are reviewed.
Collapse
Affiliation(s)
- H Ulrich Göringer
- Genetics, Darmstadt University of Technology, Schnittspahnstrasse 10, 64287 Darmstadt, Germany.
| |
Collapse
|
10
|
Cibiel A, Dupont DM, Ducongé F. Methods To Identify Aptamers against Cell Surface Biomarkers. Pharmaceuticals (Basel) 2011. [PMCID: PMC4058655 DOI: 10.3390/ph4091216] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Aptamers are nucleic acid-based ligands identified through a process of molecular evolution named SELEX (Systematic Evolution of Ligands by Exponential enrichment). During the last 10-15 years, numerous aptamers have been developed specifically against targets present on or associated with the surface of human cells or infectious pathogens such as viruses, bacteria, fungi or parasites. Several of the aptamers have been described as potent probes, rivalling antibodies, for use in flow cytometry or microscopy. Some have also been used as drugs by inhibiting or activating functions of their targets in a manner similar to neutralizing or agonistic antibodies. Additionally, it is straightforward to conjugate aptamers to other agents without losing their affinity and they have successfully been used in vitro and in vivo to deliver drugs, siRNA, nanoparticles or contrast agents to target cells. Hence, aptamers identified against cell surface biomarkers represent a promising class of ligands. This review presents the different strategies of SELEX that have been developed to identify aptamers for cell surface-associated proteins as well as some of the methods that are used to study their binding on living cells.
Collapse
Affiliation(s)
- Agnes Cibiel
- CEA, DSV, IBM, Service Hospitalier Frédéric Joliot (SHFJ), 4 place du général Leclerc, 91401 Orsay, France; E-Mail: (A.C.)
- INSERM U1023, 4 place du général Leclerc, 91401 Orsay, France
- Université Paris Sud, 4 place du général Leclerc, 91401 Orsay, France
| | - Daniel Miotto Dupont
- Department of Molecular Biology, Aarhus University, Gustav Wieds Vej 10C, 8000 Aarhus C, Denmark; E-Mail: (D.M.D.)
| | - Frédéric Ducongé
- CEA, DSV, IBM, Service Hospitalier Frédéric Joliot (SHFJ), 4 place du général Leclerc, 91401 Orsay, France; E-Mail: (A.C.)
- INSERM U1023, 4 place du général Leclerc, 91401 Orsay, France
- Université Paris Sud, 4 place du général Leclerc, 91401 Orsay, France
- Author to whom correspondence should be addressed; E-Mail: ; Tel.: +33-169-867-766; Fax: +33-169-867-786
| |
Collapse
|
11
|
Label free inhibitor screening of hepatitis C virus (HCV) NS5B viral protein using RNA oligonucleotide. SENSORS 2011; 11:6685-96. [PMID: 22163979 PMCID: PMC3231669 DOI: 10.3390/s110706685] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/11/2011] [Revised: 06/22/2011] [Accepted: 06/27/2011] [Indexed: 01/26/2023]
Abstract
Globally, over 170 million people (ca. 3% of the World's population) are infected with the hepatitis C virus (HCV), which can cause serious liver diseases such as chronic hepatitis, evolving into subsequent health problems. Driven by the need to detect the presence of HCV, as an essential factor in diagnostic medicine, the monitoring of viral protein has been of great interest in developing simple and reliable HCV detection methods. Despite considerable advances in viral protein detection as an HCV disease marker, the current enzyme linked immunosorbent assay (ELISA) based detection methods using antibody treatment have several drawbacks. To overcome this bottleneck, an RNA aptamer become to be emerged as an antibody substitute in the application of biosensor for detection of viral protein. In this study, we demonstrated a streptavidin-biotin conjugation method, namely, the RNA aptamer sensor system that can quantify viral protein with detection level of 700 pg mL(-1) using a biotinylated RNA oligonucleotide on an Octet optical biosensor. Also, we showed this method can be used to screen inhibitors of viral protein rapidly and simply on a biotinylated RNA oligonucleotide biosensor. Among the inhibitors screened, (-)-Epigallocatechin gallate showed high binding inhibition effect on HCV NS5B viral protein. The proposed method can be considered a real-time monitoring method for inhibitor screening of HCV viral protein and is expected to be applicable to other types of diseases.
Collapse
|
12
|
Mayer G, Faulhammer D, Grättinger M, Fessele S, Blind M. A RNA-based approach towards small-molecule inhibitors. Chembiochem 2009; 10:1993-6. [PMID: 19575374 DOI: 10.1002/cbic.200900325] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- Günter Mayer
- LIMES, University of Bonn, c/o Kekulé-Institut für Org. Chemie und Biochemie, 53121 Bonn (Germany).
| | | | | | | | | |
Collapse
|
13
|
Paul A, Avci-Adali M, Ziemer G, Wendel HP. Streptavidin-coated magnetic beads for DNA strand separation implicate a multitude of problems during cell-SELEX. Oligonucleotides 2009; 19:243-54. [PMID: 19732022 DOI: 10.1089/oli.2009.0194] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Using whole living cells as a target for SELEX (systematic evolution of ligands by exponential enrichment) experiments represents a promising method to generate cell receptor-specific aptamers. These aptamers have a huge potential in diagnostics, therapeutics, imaging, regenerative medicine, and target validation. During the SELEX for selecting DNA aptamers, one important step is the separation of 2 DNA strands to yield one of the 2 strands as single-stranded DNA aptamer. This is being done routinely by biotin labeling of the complementary DNA strand to the desired aptamer and then separating the DNA strand by using streptavidin-coated magnetic beads. After immobilization of the double-stranded DNA on these magnetic beads and alkaline denaturation, the non-biotinylated strand is being eluted and the biotinylated strand is retarded. Using Western blot analysis, we demonstrated the detachment of covalent-bonded streptavidin from the bead surface after alkaline treatment. The eluates were also contaminated with undesired biotinylated strands. Furthermore, a streptavidin-induced aggregation of target cells was demonstrated by flow cytometry and microscopic methods. Cell-specific enrichment of aptamers was not possible due to clustering and patching effects triggered by streptavidin. Therefore, the use of streptavidin-coated magnetic beads for DNA strand separation should be examined thoroughly, especially for cell-SELEX applications.
Collapse
Affiliation(s)
- Angela Paul
- Department of Thoracic, Cardiac, and Vascular Surgery, University Hospital, Tübingen 72076, Germany
| | | | | | | |
Collapse
|
14
|
Guo KT, Paul A, Schichor C, Ziemer G, Wendel HP. CELL-SELEX: Novel perspectives of aptamer-based therapeutics. Int J Mol Sci 2008; 9:668-678. [PMID: 19325777 PMCID: PMC2635693 DOI: 10.3390/ijms9040668] [Citation(s) in RCA: 112] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2008] [Revised: 04/03/2008] [Accepted: 04/24/2008] [Indexed: 12/15/2022] Open
Abstract
Aptamers, single stranded DNA or RNA molecules, generated by a method called SELEX (systematic evolution of ligands by exponential enrichment) have been widely used in various biomedical applications. The newly developed Cell-SELEX (cell based-SELEX) targeting whole living cells has raised great expectations for cancer biology, -therapy and regenerative medicine. Combining nanobiotechnology with aptamers, this technology opens the way to more sophisticated applications in molecular diagnosis. This paper gives a review of recent developments in SELEX technologies and new applications of aptamers.
Collapse
Affiliation(s)
- Ke-Tai Guo
- Department of Thoracic, Cardiac and Vascular surgery, University Hospital Tuebingen, Calwerstr.7/1, D72076 Tuebingen, Germany
| | - Angela Paul
- Department of Thoracic, Cardiac and Vascular surgery, University Hospital Tuebingen, Calwerstr.7/1, D72076 Tuebingen, Germany
| | - Christian Schichor
- Department of Neurosurgery, Ludwig-Maximilians-University, Klinikum Grosshadern, Marchioninistr. 15, D81377 Munich, Germany
| | - Gerhard Ziemer
- Department of Thoracic, Cardiac and Vascular surgery, University Hospital Tuebingen, Calwerstr.7/1, D72076 Tuebingen, Germany
| | - Hans P. Wendel
- Department of Thoracic, Cardiac and Vascular surgery, University Hospital Tuebingen, Calwerstr.7/1, D72076 Tuebingen, Germany
- Author to whom correspondence should be addressed; E-mail:
| |
Collapse
|
15
|
Mayer G, Wulffen B, Huber C, Brockmann J, Flicke B, Neumann L, Hafenbradl D, Klebl BM, Lohse MJ, Krasel C, Blind M. An RNA molecule that specifically inhibits G-protein-coupled receptor kinase 2 in vitro. RNA (NEW YORK, N.Y.) 2008; 14:524-534. [PMID: 18230760 PMCID: PMC2248252 DOI: 10.1261/rna.821908] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/10/2007] [Accepted: 12/07/2007] [Indexed: 05/25/2023]
Abstract
G-protein-coupled receptors are desensitized by a two-step process. In a first step, G-protein-coupled receptor kinases (GRKs) phosphorylate agonist-activated receptors that subsequently bind to a second class of proteins, the arrestins. GRKs can be classified into three subfamilies, which have been implicated in various diseases. The physiological role(s) of GRKs have been difficult to study as selective inhibitors are not available. We have used SELEX (systematic evolution of ligands by exponential enrichment) to develop RNA aptamers that potently and selectively inhibit GRK2. This process has yielded an aptamer, C13, which bound to GRK2 with a high affinity and inhibited GRK2-catalyzed rhodopsin phosphorylation with an IC50 of 4.1 nM. Phosphorylation of rhodopsin catalyzed by GRK5 was also inhibited, albeit with 20-fold lower potency (IC50 of 79 nM). Furthermore, C13 reveals significant specificity, since almost no inhibitory activity was detectable testing it against a panel of 14 other kinases. The aptamer is two orders of magnitude more potent than the best GRK2 inhibitors described previously and shows high selectivity for the GRK family of protein kinases.
Collapse
Affiliation(s)
- Günter Mayer
- Life and Medical Sciences Bonn, Program Unit Chemical Biology, c/o Kekulé-Institute for Organic Chemistry and Biochemistry, University of Bonn, Gerhard-Domagk-Strasse 1, 53121 Bonn, Germany.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Chen CK. Complex SELEX against target mixture: stochastic computer model, simulation, and analysis. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE 2007; 87:189-200. [PMID: 17624471 DOI: 10.1016/j.cmpb.2007.05.008] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/05/2007] [Revised: 05/09/2007] [Accepted: 05/16/2007] [Indexed: 05/16/2023]
Abstract
Systematic evolution of ligands by exponential enrichment (SELEX) is an important technology in combinatorial chemistry and molecular biology of developing high affinity target-binding molecules (aptamers) from highly complex nucleic acid ligand libraries. Schematically, the SELEX is a series of iterative rounds of operations where in each operational round ligands are incubated with the target (e.g., a purified protein), and target-binding ligands are extracted and amplified. In the recent development of biological study and drug discovery, by incubating ligand libraries with complex target mixtures (e.g., cell fragments), the SELEX experiments have been explored to simultaneously develop aptamers for targets embedded in target mixtures: the complex SELEX. While holding the considerable advantages of saving experimental resources, practicing the complex SELEX has often accompanied with unstable experimental performances. It is therefore important to understand the behaviors of the new application. In this paper, we develop stochastic computer model, and customized computational algorithm to numerically mimic the complex SELEX. We model the ligand selection through the probability of ligand binding to complex targets at the binding equilibrium, and efficiency of separating target-binders for amplification. The customized computational algorithm allows us to simulate real experiments that operate on huge ligand libraries. We evaluate the ligand evolution, and aptamer enrichment of complex SELEX under various experimental conditions by stochastic simulations, and theorize the simulated results. We argue that the stochastic effects, which were not previously captured in the studies of complex SELEX, may significantly affect the results of experiments.
Collapse
Affiliation(s)
- Chi-Kan Chen
- Department of Applied Mathematics, National Chung Hsing University, Taiwan.
| |
Collapse
|
17
|
Wochner A, Menger M, Rimmele M. Characterisation of aptamers for therapeutic studies. Expert Opin Drug Discov 2007; 2:1205-24. [DOI: 10.1517/17460441.2.9.1205] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
|
18
|
Stoltenburg R, Reinemann C, Strehlitz B. SELEX--a (r)evolutionary method to generate high-affinity nucleic acid ligands. ACTA ACUST UNITED AC 2007; 24:381-403. [PMID: 17627883 DOI: 10.1016/j.bioeng.2007.06.001] [Citation(s) in RCA: 937] [Impact Index Per Article: 55.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2007] [Revised: 05/31/2007] [Accepted: 06/01/2007] [Indexed: 02/07/2023]
Abstract
SELEX stands for systematic evolution of ligands by exponential enrichment. This method, described primarily in 1990 [Ellington, A.D., Szostak, J.W., 1990. In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818-822; Tuerk, C., Gold, L., 1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505-510] aims at the development of aptamers, which are oligonucleotides (RNA or ssDNA) binding to their target with high selectivity and sensitivity because of their three-dimensional shape. Aptamers are all new ligands with a high affinity for considerably differing molecules ranging from large targets as proteins over peptides, complex molecules to drugs and organic small molecules or even metal ions. Aptamers are widely used, including medical and pharmaceutical basic research, drug development, diagnosis, and therapy. Analytical and separation tools bearing aptamers as molecular recognition and binding elements are another big field of application. Moreover, aptamers are used for the investigation of binding phenomena in proteomics. The SELEX method was modified over the years in different ways to become more efficient and less time consuming, to reach higher affinities of the aptamers selected and for automation of the process. This review is focused on the development of aptamers by use of SELEX and gives an overview about technologies, advantages, limitations, and applications of aptamers.
Collapse
Affiliation(s)
- Regina Stoltenburg
- UFZ, Helmholtz Centre for Environmental Research - UFZ, Permoserstr. 15, 04318 Leipzig, Germany
| | | | | |
Collapse
|
19
|
Göringer HU, Homann M, Zacharias M, Adler A. RNA aptamers as potential pharmaceuticals against infections with African trypanosomes. Handb Exp Pharmacol 2006:375-93. [PMID: 16594626 DOI: 10.1007/3-540-27262-3_19] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
Protozoal pathogens cause symptomatic as well as asymptomatic infections. They have a worldwide impact, which in part is reflected in the long-standing search for antiprotozoal chemotherapy. Unfortunately, effective treatments for the different diseases are by and large not available. This is especially true for African trypanosomiasis, also known as sleeping sickness. The disease is an increasing problem in many parts of sub-Saharan Africa, which is due to the lack of new therapeutics and the increasing resistance against traditional drugs such as melarsoprol, berenil and isometamidium. Considerable progress has been made over the past 10 years in the development of nucleic acid-based drug molecules using a variety of different technologies. One approach is a combinatorial technology that involves an iterative Darwinian-type in vitro evolution process, which has been termed SELEX for "systematic evolution of ligands by exponential enrichment". The procedure is a highly efficient method of identifying rare ligands from combinatorial nucleic acid libraries of very high complexity. It allows the selection of nucleic acid molecules with desired functions, and it has been instrumental in the identification of a number of synthetic DNA and RNA molecules, so-called aptamers that recognize ligands of different chemical origin. Aptamers typically bind their target with high affinity and high specificity and have successfully been converted into pharmaceutically active compounds. Here we summarize the recent examples of the SELEX technique within the context of identifying high-affinity RNA ligands against the surface of the protozoan parasite Trypanosoma brucei, which is the causative agent of sleeping sickness.
Collapse
Affiliation(s)
- H U Göringer
- Genetics, Darmstadt University of Technology, Schnittspahnstr. 10, 64287 Darmstadt, Germany.
| | | | | | | |
Collapse
|
20
|
Baines IC, Colas P. Peptide aptamers as guides for small-molecule drug discovery. Drug Discov Today 2006; 11:334-41. [PMID: 16580975 DOI: 10.1016/j.drudis.2006.02.007] [Citation(s) in RCA: 73] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2005] [Revised: 12/21/2005] [Accepted: 02/17/2006] [Indexed: 11/17/2022]
Abstract
Peptide aptamers are combinatorial protein reagents that bind to target proteins with a high specificity and a strong affinity. By so doing, they can modulate the function of their cognate targets. Because peptide aptamers introduce perturbations that are similar to those caused by therapeutic molecules, their use identifies and/or validates therapeutic targets with a higher confidence level than is typically provided by methods that act upon protein expression levels. The unbiased combinatorial nature of peptide aptamers enables them to 'decorate' numerous polymorphic protein surfaces, whose biological relevance can be inferred through characterization of the peptide aptamers. Bioactive aptamers that bind druggable surfaces can be used in displacement screening assays to identify small-molecule hits to the surfaces. The peptide aptamer technology has a positive impact on drug discovery by addressing major causes of failure and by offering a seamless, cost-effective process from target validation to hit identification.
Collapse
Affiliation(s)
- Ivan C Baines
- Aptanomics, 181-203 avenue Jean Jaurès, 69007 Lyon, France
| | | |
Collapse
|
21
|
Chan R, Gilbert M, Thompson KM, Marsh HN, Epstein DM, Pendergrast PS. Co-expression of anti-NFkappaB RNA aptamers and siRNAs leads to maximal suppression of NFkappaB activity in mammalian cells. Nucleic Acids Res 2006; 34:e36. [PMID: 16517938 PMCID: PMC1390692 DOI: 10.1093/nar/gnj028] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The specific down-regulation of gene expression in cells is a powerful method for elucidating a gene's function. A common method for suppressing gene expression is the elimination of mRNA by RNAi or antisense. Alternatively, oligonucleotide-derived aptamers have been used as protein-directed agents for the specific knock-down of both intracellular and extracellular protein activity. Protein-directed methods offer the advantage of more closely mimicking small molecule therapeutics' mechanism of activity. Furthermore, protein-directed methods may synergize with RNA-directed methods since the two methods attack gene expression at different levels. Here we have knocked down a well-characterized intracellular protein's activity, NFκB, by expressing either aptamers or small interfering RNAs (siRNAs). Both methods can diminish NFκB's activity to similar levels (from 29 to 64%). Interestingly, expression of both aptamers and siRNAs simultaneously, suppressed NFκB activity better than either method alone (up to 90%). These results demonstrate that the expression of intracellular aptamers is a viable alternative to siRNA knock-down. Furthermore, for the first time, we show that the use of aptamers and siRNA together can be the most effective way to achieve maximal knock-down of protein activity.
Collapse
|
22
|
Pestourie C, Tavitian B, Duconge F. Aptamers against extracellular targets for in vivo applications. Biochimie 2006; 87:921-30. [PMID: 15963620 DOI: 10.1016/j.biochi.2005.04.013] [Citation(s) in RCA: 114] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2005] [Revised: 03/29/2005] [Accepted: 04/29/2005] [Indexed: 12/25/2022]
Abstract
Oligonucleotides are multifunctional molecules which can interfere with gene expression by different mechanism such as antisense, RNA interference, ribozymes, etc. For most in vivo diagnostic and therapeutic applications, oligonucleotides need to be delivered to the intracellular compartment of a specific organ, a difficult task which limits considerably their use. However, aptamer oligonucleotides which target extracellular markers obviate this problem. Aptamers are short oligonucleotides (<100 bases) selected from large combinatorial pools of sequences for their capacity to bind to many types of different targets, ranging from small molecules (amino acids, antibiotics...) to proteins or nucleic acid structures. Aptamers present the same high specificity and affinity for their targets as antibodies. In addition to efficient binding, aptamers have been shown in many cases to display an inhibitory activity on their targets. Moreover, they seem to lack immunogenicity and can be chemically modified in order to improve their stability against nucleases or extend their blood circulation time, two properties which are particularly useful for in vivo applications. Recently, aptamers have been selected against whole living cells, opening a new avenue which presents three major advantages 1) direct selection without prior purification of the targets; 2) conservation of membrane proteins in their native conformation similar to the in vivo conditions and 3) identification of (new) targets for a specific phenotype. Many aptamers are now being developed against biomedical relevant extracellular targets: membrane receptor proteins, hormones, neuropeptides, coagulation factors... Among them, one aptamer that inhibits the human VEGF165 has recently been approved by FDA for the treatment of age-related macular degeneration. Here we discuss the recent developments of aptamers against extracellular targets for in vivo therapy and as tools for diagnosis using molecular imaging.
Collapse
Affiliation(s)
- C Pestourie
- CEA-DSV-DRM-SHFJ, Inserm ERM 103, 4, place du general Leclerc, 91401 Orsay, France
| | | | | |
Collapse
|
23
|
Abstract
This review describes recent advances in biosensors of potential clinical applications. Biosensors are becoming increasingly important and practical tools in pathogen detection, molecular diagnostics, environmental monitoring, food safety control as well as in homeland defense. Electrochemical biosensors are particularly promising toward these goals arising due to several combined advantages including low-cost, operation convenience, and miniaturized devices. We review the clinical applications of electrochemical biosensors based on a few selected examples, including enzyme-based biosensors, immunological biosensors and DNA biosensors.
Collapse
Affiliation(s)
- Shiping Song
- Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai 201800, China
| | - Hui Xu
- Department of Chemistry, Yantai Normal University, Shandong 264025, China
| | - Chunhai Fan
- Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai 201800, China
| |
Collapse
|
24
|
Proske D, Blank M, Buhmann R, Resch A. Aptamers--basic research, drug development, and clinical applications. Appl Microbiol Biotechnol 2005; 69:367-74. [PMID: 16283295 DOI: 10.1007/s00253-005-0193-5] [Citation(s) in RCA: 159] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2005] [Revised: 08/16/2005] [Accepted: 09/14/2005] [Indexed: 01/28/2023]
Abstract
Since its discovery in the early 1990s, aptamer technology has progressed tremendously. Automated selection procedures now allow rapid identification of DNA and RNA sequences that can target a broad range of extra- and intracellular proteins with nanomolar affinities and high specificities. The unique binding properties of nucleic acids, which are amenable to various modifications, make aptamers perfectly suitable for different areas of biotechnology. Moreover, the approval of an aptamer for vascular endothelial growth factor by the US Food and Drug Administration highlights the potential of aptamers for therapeutic applications. This review summarizes recent developments and demonstrates that aptamers are valuable tools for diagnostics, purification processes, target validation, drug discovery, and even therapeutic approaches.
Collapse
Affiliation(s)
- Daniela Proske
- NascaCell IP GmbH, 3. OG, Modul D Max-Lebsche-Platz, 3181377 Munich, Germany.
| | | | | | | |
Collapse
|
25
|
Blank M, Blind M. Aptamers as tools for target validation. Curr Opin Chem Biol 2005; 9:336-42. [PMID: 16006181 DOI: 10.1016/j.cbpa.2005.06.011] [Citation(s) in RCA: 90] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2005] [Accepted: 06/22/2005] [Indexed: 11/16/2022]
Abstract
Synthetic nucleic acid ligands, called aptamers, bind to protein targets with high specificity and affinity. They are very potent inhibitors of protein function and their application can greatly enhance the process of target validation and drug development. An important benefit of this technology is the recent development of rapidly identifying these sophisticated ligands for almost any target molecule in multi-parallel, automated workstations. The aptamer technology is thus well-suited to addressing the growing demand for high-throughput analysis and functional validation of potential drug targets. Numerous examples have shown the potency of aptamers in inhibiting the function of proteins in cell culture and in vivo models. The technology is complementary to genetic knockout or siRNA approaches as it provides highly valuable information at the proteomic level. In addition, the aptamer technology has recently been extended to developing aptamer drugs and identifying functionally equivalent small molecule leads.
Collapse
|
26
|
Abstract
Aptamers are short single-stranded oligonucleotides that fold into well defined three-dimensional shapes allowing them to bind to and inhibit their targets with high affinity and specificity. Aptamers can be considered truly multifunctional tools, because they can be generated rapidly and applied for specific detection, inhibition, and characterization of proteins. Recent publications impressively confirm that aptamers can be used either as surrogate inhibitors for the identification of small molecule lead compounds or as biopharmaceuticals.
Collapse
|
27
|
Abstract
Nucleic acid aptamers are molecules that bind to their ligands with high affinity and specificity. Unlike other functional nucleic acids such as antisense oligonucleotides, ribozymes, or siRNAs, aptamers almost never exert their effects on the genetic level. They manipulate their target molecules such as gene products or epitopes directly and site specifically, leaving nontargeted protein functions intact. In a similar way to antibodies, aptamers bind to many different kinds of target molecules with high specificity and can be made to order, but as a result of their different biochemical nature and size they can also be used complementary to antibodies. In some cases, aptamers might be more suitable or more specific than antibody approaches or small molecules, both as scientific and biotechnological tools and as therapeutic agents. Recent examples of characterization of aptamers as tools for scientific research to study regulatory circuits, as tools in diagnostic or biosensor development, and as therapeutic agents are discussed.
Collapse
Affiliation(s)
- Martina Rimmele
- Research & Development, RiNA Netzwerk RNA Technologien GmbH, Takustrasse 3, 14195 Berlin, Germany.
| |
Collapse
|
28
|
Jain KK. Proteomic technologies for cancer target validation. DRUG DISCOVERY TODAY. TECHNOLOGIES 2004; 1:75-78. [PMID: 24981374 DOI: 10.1016/j.ddtec.2004.06.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Genomic and proteomic technologies have produced an abundance of drug targets, which is creating a bottleneck in drug development process. There is an increasing need for better target validation for cancer drug development and proteomic technologies are contributing to it. These technologies are compared to enable the selection of the one by matching the needs of a particular project. There are prospects for further improvement, and proteomics technologies will form an important addition to the existing genomic and chemical technologies for target validation.
Collapse
Affiliation(s)
- K K Jain
- Jain PharmaBiotech, Blaesiring 7, 4057 Basel, Switzerland. http://pharmabiotech.ch
| |
Collapse
|
29
|
Ilyin SE, Bernal A, Horowitz D, Derian CK, Xin H. Functional informatics: convergence and integration of automation and bioinformatics. Pharmacogenomics 2004; 5:721-30. [PMID: 15335292 DOI: 10.1517/14622416.5.6.721] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
The biopharmaceutical industry is currently being presented with opportunities to improve research and business efficiency via automation and the integration of various systems. In the examples discussed, industrial high-throughput screening systems are integrated with functional tools and bioinformatics to facilitate target and biomarker identification and validation. These integrative functional approaches generate value-added opportunities by leveraging available automation and information technologies into new applications that are broadly applicable to different types of projects, and by improving the overall research and development and business efficiency via the integration of various systems.
Collapse
Affiliation(s)
- Sergey E Ilyin
- Johnson & Johnson Pharmaceutical Research & Development, LLC, Welsh and McKean Roads, Spring House, PA 19477-0776, USA.
| | | | | | | | | |
Collapse
|
30
|
Hwang B, Cho JS, Yeo HJ, Kim JH, Chung KM, Han K, Jang SK, Lee SW. Isolation of specific and high-affinity RNA aptamers against NS3 helicase domain of hepatitis C virus. RNA (NEW YORK, N.Y.) 2004; 10:1277-1290. [PMID: 15247433 PMCID: PMC1370617 DOI: 10.1261/rna.7100904] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/29/2004] [Accepted: 05/12/2004] [Indexed: 05/24/2023]
Abstract
Hepatitis C virus (HCV)-encoded nonstructural protein 3 (NS3) possesses protease, NTPase, and helicase activities, which are considered essential for viral proliferation. Thus, HCV NS3 is a good putative therapeutic target protein for the development of anti-HCV agents. In this study, we isolated specific RNA aptamers to the helicase domain of HCV NS3 from a combinatorial RNA library with 40-nucleotide random sequences using in vitro selection techniques. The isolated RNAs were observed to very avidly bind the HCV helicase with an apparent Kd of 990 pM in contrast to original pool RNAs with a Kd of >1 microM. These RNA ligands appear to impede binding of substrate RNA to the HCV helicase and can act as potent decoys to competitively inhibit helicase activity with high efficiency compared with poly(U) or tRNA. The minimal binding domain of the ligands was determined to evaluate the structural features of the isolated RNA molecules. Interestingly, part of binding motif of the RNA aptamers consists of similar secondary structure to the 3'-end of HCV negative-strand RNA. Moreover, intracellular NS3 protein can be specifically detected in situ with the RNA aptamers, indicating that the selected RNAs are very specific to the HCV NS3 helicase. Furthermore, the RNA aptamers partially inhibited RNA synthesis of HCV subgenomic replicon in Huh-7 hepatoma cell lines. These results suggest that the RNA aptamers selected in vitro could be useful not only as therapeutic and diagnostic agents of HCV infection but also as a powerful tool for the study of HCV helicase mechanism.
Collapse
Affiliation(s)
- Byounghoon Hwang
- Department of Molecular Biology, Institute of Nanosensor and Biotechnology, Dankook University, San8 Hannam-Dong, Yongsan-Gu, Seoul 140-714, Korea
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Göringer HU, Homann M, Lorger M. In vitro selection of high-affinity nucleic acid ligands to parasite target molecules. Int J Parasitol 2003; 33:1309-17. [PMID: 14527514 DOI: 10.1016/s0020-7519(03)00197-8] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
The logic of using nucleic acids as pharmaceutical reagents is in part based on their capacity to interact with high affinity and specificity with other biological components. Considerable progress has been made over the past 10 years in the development of nucleic acid-based drug molecules using a variety of different technologies. One approach is a combinatorial technology that involves an iterative Darwinian-type in vitro evolution process, which has been termed SELEX for 'systematic evolution of ligands by exponential enrichment'. The procedure is a highly efficient method of identifying rare ligands from combinatorial nucleic acid libraries of very high complexity. It allows the selection of nucleic acid molecules with desired functions and it has been instrumental in the identification of a number of synthetic DNA and RNA molecules, so-called aptamers that recognise ligands of different chemical origin. The method is fast, it does not require special equipment and the selected aptamers typically bind their target with high affinity and high specificity. Here we summarise the recent examples of the SELEX technique within the context of identifying high-affinity ligands against parasite target molecules.
Collapse
Affiliation(s)
- H Ulrich Göringer
- Department of Microbiology and Genetics, Darmstadt University of Technology, Schnittspahnstrasse 10, 64287 Darmstadt, Germany.
| | | | | |
Collapse
|
32
|
Abstract
Target discovery, which involves the identification and early validation of disease-modifying targets, is an essential first step in the drug discovery pipeline. Indeed, the drive to determine protein function has been stimulated, both in industry and academia, by the completion of the human genome project. In this article, we critically examine the strategies and methodologies used for both the identification and validation of disease-relevant proteins. In particular, we will examine the likely impact of recent technological advances, including genomics, proteomics, small interfering RNA and mouse knockout models, and conclude by speculating on future trends.
Collapse
Affiliation(s)
- Mark A Lindsay
- AstraZeneca Pharmaceuticals, 19F19 Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.
| |
Collapse
|
33
|
|
34
|
Coleman RA, Clark KL. Target validation using human tissue: from gene expression to function. ACTA ACUST UNITED AC 2003. [DOI: 10.1016/s1477-3627(03)02298-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|